Home Search

eoe - search results

If you're not happy with the results, please do another search
The Food Allergy Institute

Over 8,000 Food Allergy Patients in Remission with the Tolerance Induction Program™ (TIP)

0
TIP helps food allergy patients regain their confidence and achieve food freedom, or the ability to eat whatever they want, whenever they want, without restriction.
Revolo Biotherapeutics '1104

Peptide Shows Promise as an Allergen-Agnostic Treatment for Food Allergy

0
Revolog presents new data demonstrating long-lasting effect of '1104 candidate.
Mast Cells

Allakos Announces New Antibody that Prevents Anaphylaxis in Humanized Mice

0
Company will initiate human trials next year.
AIM_Palforzia_SnackSafely_Article_Holiday_imagesFamily

This Holiday Season, See the Potential Impact that Peanut Allergy Treatment Can Make

0
Did you know there’s a treatment option in addition to avoidance alone?
CHOP Dupilumab Study

CHOP Receives $2M Philanthropic Gift to Launch Food Allergy Study Using Dupilumab

0
"A successful clinical trial would open the possibility of food introduction to more than 3,500 CHOP patients with EoE."

Notebooks, check. Backpack, check. Peanut allergy treatment, check.

0
What if you could give your child a treatment option, in addition to practicing a strict peanut-free diet?
Tanya Ednan-Laperouse and Emma Turay

Two UK Allergy Moms Who Suffered Horrific Losses Demand an Allergy Czar. We Should...

2
We applaud the efforts of Ms Ednan-Laperouse and Ms Turay and believe their concept of a single person responsible for the health and safety of the allergic community should be adopted here in the US.
Palforzia Ad

How the First FDA-Approved Therapy for Peanut Allergy is Helping Families

0
What is PALFORZIA?  PALFORZIA is a treatment for people who are allergic to peanuts. PALFORZIA can help reduce the severity of allergic reactions, including anaphylaxis,...
Dupixent (dupilumab)

Dupixent (dupilumab) Study Shows Significant Improvement in Eosinophilic Esophagitis Signs and Symptoms

Phase 3 trial in (EoE) to show a significantly improved structural and histologic measures, while rapidly improving ability to swallow in patients 12 years and older